Results 11 to 20 of about 12,085 (139)

Ubiquitin-dependent Down-regulation of the Neurokinin-1 Receptor [PDF]

Journal of Biological Chemistry, 2006
Transient stimulation with substance P (SP) induces endocytosis and recycling of the neurokinin-1 receptor (NK(1)R). The effects of sustained stimulation by high concentrations of SP on NK(1)R trafficking and Ca(2+) signaling, as may occur during chronic inflammation and pain, are unknown. Chronic exposure to SP (100 nm, 3 h) completely desensitized Ca(
Graeme S, Cottrell, Benjamin, Padilla, Stella, Pikios, Dirk, Roosterman, Martin, Steinhoff, Daphne, Gehringer, Eileen F, Grady, Nigel W, Bunnett   +7 more
openaire   +2 more sources

The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and Cancer [PDF]

The Scientific World Journal, 2012
The recent years have witnessed an exponential increase in cancer research, leading to a considerable investment in the field. However, with few exceptions, this effort has not yet translated into a better overall prognosis for patients with cancer, and the search for new drug targets continues.
Marisa Rosso, Miguel Muñoz, Michael Berger   +2 more
openaire   +3 more sources

Chemotherapy‐Activated GSK3β‐DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma

Advanced Science, EarlyView.
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Jie Li, Shuai Ying, Yi Zhang, Jingjing Wang, Quan Wan, Lingli Gong, Daxing Xu, Zhenkun Yang, Hongnian Lu, Ying Yin, Xiangming Fang, Zhening Pu   +11 more
wiley   +1 more source

Neurovascular coupling in bone regeneration: Mechanisms, advanced biomaterials and challenges

BMEMat, EarlyView.
This figure illustrates various material strategies for neurovascularized bone regeneration, including electroactive scaffolds, ion‐loaded materials, drug delivery systems, surface modifications, cells/cell products, growth factors, and peptides. These approaches aim to synergistically promote the regeneration of neural, vascular, and bone tissues ...
Yixin Ma, Nan Jiang, Liyuan Chen, He Zhang, Xinjia Cai, Karan Gulati, Danqing He, Zhigang Cai, Yan Liu   +8 more
wiley   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Factors Associated With Non‐Vasomotor Menopause Symptoms Experienced by 7285 Women: A UK‐Wide National Survey

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To investigate the factors associated with non‐vasomotor menopause symptoms among women in the UK, focusing on the perceived importance of specific symptoms and their association with demographic and treatment‐related factors. Design A cross‐sectional online survey.
Rhianna Davies, Ashwin Goyal, Zachary Nash, Sarah Hillman, Melanie Davies, Nick Panay, Jane Daniels, Tim Hillard, Bonnie Grant, Paula Briggs, Lynne Robinson, Haitham Hamoda, Channa N. Jayasena   +12 more
wiley   +1 more source

Modern Management of the Menopause: Are We Measuring What Matters?

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective Assess uptake of the Core Outcomes in Menopause (COMMA) core outcome sets (COS) and examine whether frontline treatments for vasomotor and genitourinary symptoms have been evaluated against these key outcomes. Design Methodological review. Setting Published literature and international clinical trial registries.
Joscelyn Gan, Michelle Steeper, Tim Hillard, Monica Christmas, Jan Shifren, Nick Panay, Martha Hickey, Sarah Lensen   +7 more
wiley   +1 more source

Comparative Efficacy of Elinzanetant Versus Other Non‐Hormonal Pharmaceutical Therapies for the Treatment of Moderate‐to‐Severe Vasomotor Symptoms Associated With Menopause: A Network Meta‐Analysis

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Elinzanetant, a novel, dual neurokinin‐targeted therapy, has been approved in various geographies for the treatment of moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non‐hormonal pharmaceutical treatments (nHT) in alleviating VMS.
Piotr Wojciechowski, Klaudia Kolonko, Andromachi Giannopoulou, Beata Smela, Elżbieta Olewinska, Kristina Rosa Bolling, Jenifer Sassarini, Lee P. Shulman, Vikram Talaulikar   +8 more
wiley   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

The Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis

Allergy, EarlyView.
ABSTRACT Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...
Peter K. Smith, Nicholas P. West, Stanley Du Preez, Hugh A. Sampson, Peter W. Hellings, David Price, Liam O'Mahony, Carina Venter, Cezmi A. Akdis, Gil Yosipovitch   +9 more
wiley   +1 more source